The keywords selected were "Cancer Immunotherapy," "Programmed Cell Death Ligand 1," "Programmed Cell Death Protein 1," "Immune Checkpoint Inhibitors," "Pembrolizumab Clinical Trials," and "Immunotherapy Resistance." The gene discussed is PDCD1; the disease is cancer.